A citation-based method for searching scientific literature

S Gadgeel, S Peters, T Mok, A T Shaw, D W Kim, S I Ou, M Pérol, A Wrona, S Novello, R Rosell, A Zeaiter, T Liu, E Nüesch, B Balas, D R Camidge. Ann Oncol 2018
Times Cited: 148







List of co-cited articles
920 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
52

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
634
37

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
437
35

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
371
35

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
35

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,[...]. Lancet 2017
535
32

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
S Novello, J Mazières, I-J Oh, J de Castro, M R Migliorino, Å Helland, R Dziadziuszko, F Griesinger, A Kotb, A Zeaiter,[...]. Ann Oncol 2018
153
26

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, Benjamin J Solomon, Gregory J Riely, Myung-Ju Ahn, Caicun Zhou, S Martin Shreeve, Paulina Selaru, Anna Polli,[...]. J Clin Oncol 2015
444
26

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
247
26

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
25

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, Manuel Cobo, Eun Kyung Cho, Alessandro Bertolini, Sabine Bohnet, Caicun Zhou, Ki Hyeong Lee, Naoyuki Nogami,[...]. J Clin Oncol 2018
311
25

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se-Hoon Lee, Lilian Bu,[...]. Lancet Respir Med 2019
99
23

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
132
23

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
22

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
376
21

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
649
20

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, Karen L Reckamp, Karin Holmskov Hansen, Sang-We Kim, Rudolf M Huber, Howard L West, Harry J M Groen, Maximilian J Hochmair,[...]. J Clin Oncol 2017
367
19

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Alice T Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok,[...]. Lancet Oncol 2017
319
19

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
T Mok, D R Camidge, S M Gadgeel, R Rosell, R Dziadziuszko, D-W Kim, M Pérol, S-H I Ou, J S Ahn, A T Shaw,[...]. Ann Oncol 2020
149
19

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis,[...]. J Thorac Oncol 2019
201
18

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
William J Magnuson, Nataniel H Lester-Coll, Abraham J Wu, T Jonathan Yang, Natalie A Lockney, Naamit K Gerber, Kathryn Beal, Arya Amini, Tejas Patil, Brian D Kavanagh,[...]. J Clin Oncol 2017
254
17

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Yiyun Tang,[...]. J Clin Oncol 2018
207
17

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
16

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, Fiona H Blackhall, Daniel B Costa, Dong-Wan Kim, Kazuhiko Nakagawa, Yi-Long Wu, Tarek Mekhail, Jolanda Paolini,[...]. J Clin Oncol 2016
161
15

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
Deepa Rangachari, Norihiro Yamaguchi, Paul A VanderLaan, Erik Folch, Anand Mahadevan, Scott R Floyd, Erik J Uhlmann, Eric T Wong, Suzanne E Dahlberg, Mark S Huberman,[...]. Lung Cancer 2015
258
14

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Kimberly L Johung, Norman Yeh, Neil B Desai, Terence M Williams, Tim Lautenschlaeger, Nils D Arvold, Matthew S Ning, Albert Attia, Christine M Lovly, Sarah Goldberg,[...]. J Clin Oncol 2016
232
14

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
455
14

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Kazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara, Masahiro Morise, Koichi Azuma, Young Hak Kim, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka,[...]. Lung Cancer 2020
45
31

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Shirish M Gadgeel, Leena Gandhi, Gregory J Riely, Alberto A Chiappori, Howard L West, Michele C Azada, Peter N Morcos, Ruey-Min Lee, Linta Garcia, Li Yu,[...]. Lancet Oncol 2014
502
13

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Makoto Nishio, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Tomohiro Tanaka, Hiroshi Kuriki, Ali Zeaiter, Tomohide Tamura. Lung Cancer 2018
42
30

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Rudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, Howard L West, Karen L Reckamp, Natasha B Leighl, Marcello Tiseo, Egbert F Smit, Dong-Wan Kim, Scott N Gettinger,[...]. J Thorac Oncol 2020
69
18

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Sarah B Goldberg, Scott N Gettinger, Amit Mahajan, Anne C Chiang, Roy S Herbst, Mario Sznol, Apostolos John Tsiouris, Justine Cohen, Alexander Vortmeyer, Lucia Jilaveanu,[...]. Lancet Oncol 2016
650
13

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Alice T Shaw, Leena Gandhi, Shirish Gadgeel, Gregory J Riely, Jeremy Cetnar, Howard West, D Ross Camidge, Mark A Socinski, Alberto Chiappori, Tarek Mekhail,[...]. Lancet Oncol 2016
463
12

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Yi-Long Wu, Myung-Ju Ahn, Marina Chiara Garassino, Ji-Youn Han, Nobuyuki Katakami, Hye Ryun Kim, Rachel Hodge, Paramjit Kaur, Andrew P Brown, Dana Ghiorghiu,[...]. J Clin Oncol 2018
227
12

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.
Paul D Brown, Kurt Jaeckle, Karla V Ballman, Elana Farace, Jane H Cerhan, S Keith Anderson, Xiomara W Carrero, Fred G Barker, Richard Deming, Stuart H Burri,[...]. JAMA 2016
804
12

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
898
12

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
636
12

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Sarah B Goldberg, Kurt A Schalper, Scott N Gettinger, Amit Mahajan, Roy S Herbst, Anne C Chiang, Rogerio Lilenbaum, Frederick H Wilson, Sacit Bulent Omay, James B Yu,[...]. Lancet Oncol 2020
183
12

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.
Hidefumi Aoyama, Hiroki Shirato, Masao Tago, Keiichi Nakagawa, Tatsuya Toyoda, Kazuo Hatano, Masahiro Kenjyo, Natsuo Oya, Saeko Hirota, Hiroki Shioura,[...]. JAMA 2006
12

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Shirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, Leena Gandhi, Mark A Socinski, D Ross Camidge, Luigi De Petris, Dong-Wan Kim, Alberto Chiappori, Denis L Moro-Sibilot,[...]. J Clin Oncol 2016
128
12

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li,[...]. J Clin Oncol 2019
169
11

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Tatsushi Kodama, Masami Hasegawa, Kenji Takanashi, Yuji Sakurai, Osamu Kondoh, Hiroshi Sakamoto. Cancer Chemother Pharmacol 2014
173
11

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
11

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
11

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
11

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
11

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Alexander Drilon, Jessica J Lin, Thomas Filleron, Ai Ni, Julie Milia, Isabella Bergagnini, Vaios Hatzoglou, Vamsidhar Velcheti, Michael Offin, Bob Li,[...]. J Thorac Oncol 2018
73
15

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Georgina V Long, Victoria Atkinson, Serigne Lo, Shahneen Sandhu, Alexander D Guminski, Michael P Brown, James S Wilmott, Jarem Edwards, Maria Gonzalez, Richard A Scolyer,[...]. Lancet Oncol 2018
491
11

Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.
Masaaki Yamamoto, Toru Serizawa, Takashi Shuto, Atsuya Akabane, Yoshinori Higuchi, Jun Kawagishi, Kazuhiro Yamanaka, Yasunori Sato, Hidefumi Jokura, Shoji Yomo,[...]. Lancet Oncol 2014
759
11

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, Harry J M Groen, Heather Wakelee, Toyoaki Hida, Tony Mok, David Spigel, Enriqueta Felip, Makoto Nishio,[...]. J Clin Oncol 2016
243
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.